GridAI Technologies Corp 2026年季度报告

Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934 during thepreceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past90days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of theExchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ There were 6,653,140shares of the registrant’s common stock, par value $0.0001 per share (the “Common Stock”), outstanding as of May 27, 2026. TABLE OF CONTENTS PagePART I. FINANCIAL INFORMATIONItem 1. Unaudited Condensed Consolidated Financial Statements1Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations32Item 3.Quantitative and Qualitative Disclosures About Market Risk41Item 4. Controls and Procedures41PART II. OTHER INFORMATIONItem 1.Legal Proceedings42Item1A.Risk Factors42Item 2.Unregistered Sales of Equity Securities and Use of Proceeds42Item 3.Defaults Upon Senior Securities42Item 4.Mine Safety Disclosures42Item 5. Other Information42Item 6. Exhibits43SIGNATURES CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ThisQuarterly Report on Form 10-Q(“Quarterly Report”)contains forward-looking statements that involvesubstantial risks and uncertainties. All statements contained in this Quarterly Report other than statements of historicalfacts, including statements regarding our strategy, future operations, future financial position, future revenue, projectedcosts, prospects, plans, objectives of management and expected market growth, are forward-looking statements. Thesestatements involve known and unknown risks, uncertainties and other important factors that may cause our actualresults, performance or achievements to be materially different from any future results, performance or achievementsexpressed or implied by the forward-looking statements. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “target”,“potential”, “will”, “would”, “could”, “should”, “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: ●our ability to maintain compliance with the applicable listing requirements of The Nasdaq Capital Market;●our ability to satisfy our existing payment obligations and other payment obligations as they become due,including those related to the acquisition of First Wave Bio, Inc.●statements regarding the impact of geopolitical events, including the war in Ukraine and the Middle East, andtheir effects on our operations, access to capital, research and development and clinical trials and potentialdisruption in the operations and business of third-party vendors, contract research organizations (“CROs”),contractdevelopment and manufacturing organizations(“CDMOs”),other service providers,andcollaborators with whom we conduct business;●the availability of capital to satisfy our working capital requirements;●our current and future capital requirements and our ability to raise additional funds to satisfy our capitalneeds;●our ability to consummate our disposal of our IMGX subsidiary and related liabilities;●the accuracy of our estimates regarding expense, future revenue and capital requirements;●our ability to continue operating as a going concern;●our plans to develop and commercialize our product candidates, including Adrulipase,●our ability to initiate and complete our clinical trials and to advance our principal product candidates intoadditional clinical trials, including pivotal clinical trials, and successfully complete such clinical trials;●regulatory developments in the U.S. and foreign countries;●the performance of our third-party vendor(s), CROs, CDMOs and other third-party non-clinical and clinicaldevelopment collaborators and regulatory service providers;●our ability to obtain and maintain intellectual property protection for our core assets;●the size of the potential markets for